Hormonal Contraception and Breast Cancer Risk

American journal of lifestyle medicine, 12(3), 224-226

DOI 10.1177/1559827618754833 PMID 30283254

Abstract

Contemporary hormonal contraception formulations contain lower doses of estrogen, have new synthetic progestin components, and provide novel methods of delivery that have not been studied extensively in relation to breast cancer risk. Given that hormonal contraception is the leading method of birth control in the United States, it is important to reevaluate risk using current formulations. Recent studies including contemporary hormonal contraception formulations will be described.

Topics

White hormonal contraception breast cancer risk contemporary formulations review, lower dose estrogen new synthetic progestin breast cancer risk hormonal contraception, combined oral contraceptive breast cancer relative risk prospective cohort evidence, hormonal patch ring implant breast cancer risk newer delivery methods, 1.2 million Danish women hormonal contraception breast cancer Morch 2017 study, American Journal Lifestyle Medicine 2018 hormonal contraception breast cancer risk, estrogen-progestin contraceptive duration breast cancer risk dose-response relationship, progestin-only pill IUD injectable breast cancer risk versus combined methods, contemporary hormonal contraception low-dose formulations breast cancer evidence, hormonal contraception informed consent breast cancer risk prescribing counseling
PMID 30283254 30283254 DOI 10.1177/1559827618754833 10.1177/1559827618754833

Cite this article

White, N. D. (2018). Hormonal Contraception and Breast Cancer Risk. *American journal of lifestyle medicine*, *12*(3), 224-226. https://doi.org/10.1177/1559827618754833

Related articles